AGP Executive Report
Last update: 10 hours agoCancer Research in Chicago: New ASCO updates highlight multiple oncology advances, including Percheron Therapeutics’ HMBD-002 preclinical work pointing to VISTA as a possible driver of triple-negative breast cancer resistance, and phase 3 ASCENT-04 data showing sacituzumab govitecan plus pembrolizumab improves longer-term PFS2 versus chemo plus pembrolizumab in PD-L1+ mTNBC. Targeted Radioligand Therapy: UroToday reports on CONVERGE-01 Part 3 testing Ac-225 rosopatamab tetraxetan (CONV01-α) in PSMA-pretreated metastatic castration-resistant prostate cancer, emphasizing tumor uptake and reduced salivary/kidney uptake. Illinois Courts & Public Safety Tech: Illinois lawmakers passed a bill requiring pretrial service agencies to send three court-date reminder texts to people on pretrial release, with funding for counties that need to catch up. Cybersecurity & Insurance: A Chicago CEO warns that cyber insurance claims are often denied when MFA isn’t fully enforced, citing NAIC and industry claim statistics. Opioid Crisis Watch: A report flags “orphines,” synthetic opioids described as far more potent than fentanyl, as a growing street threat. Environment & Infrastructure: A stormwater improvement project is set to begin on West Illinois Street in Kirksville, with a multi-week closure expected.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
